HC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $44.00

Bicara Therapeutics (NASDAQ:BCAX) had its price target cut by HC Wainwright from $45.00 to $44.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $10.40 on Monday. Bicara Therapeutics has a 1-year low of $8.91 and a 1-year high of $28.09. The business has a 50 day simple moving average of $12.84 and a two-hundred day simple moving average of $17.03.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). As a group, equities analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC purchased a new position in Bicara Therapeutics during the third quarter worth approximately $1,239,000. Wellington Management Group LLP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $19,458,000. The Manufacturers Life Insurance Company purchased a new stake in Bicara Therapeutics in the 3rd quarter worth $582,000. Barclays PLC purchased a new stake in Bicara Therapeutics in the 3rd quarter worth $255,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics during the third quarter worth $309,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.